The charges claim Apotex worked with other drug companies to increase and maintain the price of pravastatin, a cholesterol drug that lowers the risk of heart disease and stroke, from 2013 to 2015.
Apotex agreed to pay $24.1 million as part of a deferred prosecution agreement. Under the agreement, Apotex is required to cooperate with the government’s broader investigation into generic drug pricing and put in place a program to detect and prevent future antitrust violations.
In return, the Justice Department will defer any prosecution for three years and drop the price-fixing charge if Apotex cooperates.
Read the full news release here.
More articles on pharmacy:
CVS’ goal of opening 1,500 HealthHubs on track despite pandemic
FDA adds heartburn drug being tested to treat COVID-19 to shortage list
Drug transport costs jump 224% amid COVID-19 pandemic, survey finds
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
